Novel digital therapy could help relieve migraines
The U.S. Food and Drug Administration has authorized the use of a novel prescription digital therapeutic to prevent episodic migraines.
The authorization allows for the smartphone-based application, known as CT-132, to be prescribed as an adjunctive therapy alongside acute and/or preventive pharmacologic treatments, according to a news report from Fierce Biotech. In a clinical trial, CT-132 was found to reduce monthly migraine days as well as improve quality of life and migraine-related disability compared with a sham digital control.
The authorization represents the potential to expand access to care among patients with migraines.
Read more: Fierce Biotech
The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.